| Accession Number: | 0001626199-21-000112 |
| Date: | 2021-09-17 |
| Issuer: | ALPINE IMMUNE SCIENCES, INC. (ALPN) |
| Original Submission Date: |
CUI XIANGMIN
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE, WA 98102
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2021-09-17 | P | 1,542,553 | a | $9.40 | 4,708,288 | indirect | f1 |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|
| ID | footnote |
|---|---|
| f1 | the reportable securities are owned directly by decheng capital china life sciences usd fund iii, l.p. (the "fund"). the reporting person is the manager of the general partner of the fund. the reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interests therein. |
